Fluvoxamine pharmacotherapy of anxiety disorders in later life: Preliminary open-trial data

Mary E. Wylie, Mark D. Miller, M. Katherine Shear, John T. Little, Benoit H. Mulsant, Bruce G. Pollock, Charles F. Reynolds

Research output: Contribution to journalArticlepeer-review


The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation.

Original languageEnglish (US)
Pages (from-to)43-48
Number of pages6
JournalJournal of Geriatric Psychiatry and Neurology
Issue number1
StatePublished - Jan 1 2000

ASJC Scopus subject areas

  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Fluvoxamine pharmacotherapy of anxiety disorders in later life: Preliminary open-trial data'. Together they form a unique fingerprint.

Cite this